Indaptus Therapeutics Inc. (INDP)

Name: Indaptus Therapeutics Inc. (INDP) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Indaptus Therapeutics Inc. (INDP)

Stock Card

$1.12

$-0.02 (-2.17%)

As on 01-Sep-2026 11:37EDT

Market cap

$155 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

13.7

Div. Yield

0 %

Indaptus Therapeutics (INDP) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 1.10 High: 1.16

52 Week Range

Low: 0.92 High: 8.57

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-3.2 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

1
Debt to Equity

0
Book Value

$--
EPS

$-7
Face value

--
Shares outstanding

133,242,324

5 Years Aggregate

CFO

$-70.14 Mln

EBITDA

$-76.70 Mln

Net Profit

$-88.02 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Indaptus Therapeutics (INDP)	-61.5	-13.2	-36.4	-82.8	-76.0	-67.2	-60.9
BSE Sensex	-9.1	-1.5	2.9	-3.6	5.9	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
Indaptus Therapeutics (INDP)	-87.7	-51.9	21.4	-74.6	-58.7	-65.5	-93.4
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Indaptus Therapeutics (INDP)	1.1	154.6	0.0	-15.4	--	-212.4	--	13.7
Arrowhead Pharmaceuticals (ARWR)	82.7	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Ascendis Pharma A/S - ADR	262.1	16,261.1	1,054.4	755.9	5.7	--	19	9.8
Cytokinetics Inc (CYTK)	71.2	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	55.5	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	107.4	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	361.4	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	539.7	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	585.2	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	350.4	9,625.4	0.0	-339.1	--	-30.6	--	7.6

Shareholding Pattern

View Details

About Indaptus Therapeutics (INDP)

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity... and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. Read more

CEO & Director

Mr. Jeffrey A. Meckler
Founder, Chief Scientific Officer & Director

Dr. Michael J. Newman Ph.D.
Headquarters

New York, NY
Website

https://indaptusrx.com

FAQs for Indaptus Therapeutics (INDP)

What is the current share price of Indaptus Therapeutics Inc (INDP) Today?

The share price of Indaptus Therapeutics Inc (INDP) is $1.12 (NASDAQ) as of 01-Sep-2026 11:37 EDT. Indaptus Therapeutics Inc (INDP) has given a return of -75.96% in the last 3 years.

What is the current PB & PE ratio of Indaptus Therapeutics Inc (INDP)?

Since, TTM earnings of Indaptus Therapeutics Inc (INDP) is negative, P/E ratio is not available.
The P/B ratio of Indaptus Therapeutics Inc (INDP) is 13.71 times as on 28-Aug-2026, a 165 premium to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-0.30	2.00
2024	-0.52	2.00
2023	-0.96	1.22
2022	-0.84	0.49
2021	-3.02	0.65

What is the 52 Week High and Low of Indaptus Therapeutics Inc (INDP)?

The 52-week high and low of Indaptus Therapeutics Inc (INDP) are Rs 8.57 and Rs 0.92 as of 01-Sep-2026.

What is the market cap of Indaptus Therapeutics Inc (INDP)?

Indaptus Therapeutics Inc (INDP) has a market capitalisation of $ 155 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Indaptus Therapeutics Inc (INDP)?

Before investing in Indaptus Therapeutics Inc (INDP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.